Advancing T Cell Engagers for Solid Tumors
next generation t cell engagers
Context Therapeutics is committed to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. The company’s innovative pipeline features clinical-stage bispecific therapeutics designed to harness the immune system for targeted cancer eradication.
Portfolio Highlights
CTIM-76: a selective Claudin 6 (CLDN6) x CD3 bispecific antibody
CT-95: an avidity enhanced and affinity tuned mesothelin (MSLN) x CD3 bispecific antibody
CT-202: a dual pH-dependent Nectin-4 x CD3 bispecific antibody
With a focus on innovative immunotherapeutic solutions, Context is dedicated to transforming the landscape of cancer care and improving outcomes for patients with difficult-to-treat solid tumors.